pharmaceutical investing Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
pharmaceutical investing Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
LaFleur Minerals Commences Diamond Drilling at the Swanson Gold Deposit and Completes Independent Valuation of the Beacon Gold Mill
